Journal Home
Search for

Volume 29, Issue 7, Pages 450-453 (August 2007)


View previous. 12 of 17 View next.

Treatment of symptomatic heterozygous aceruloplasminemia with oral zinc sulphate

J. KuhnaCorresponding Author Informationemail address, H. Bewermeyerb, H. Miyajimac, Y. Takahashic, K.F. Kuhnd, T.U. Hoogenraade

Received 5 November 2006; received in revised form 21 December 2006; accepted 10 January 2007.

Abstract 

Aceruloplasminemia is an autosomal recessive and phenotypically primarily neurodegenerative disease caused by a homozygous mutation of the ceruloplasmin gene. The absence of ceruloplasmin and its ferroxidase activity leads to pathological iron overload in the brain and other organs. While heterozygous carriers of ceruloplasmin gene mutations have been believed to be asymptomatic, a number of cases with neurological deficits have recently been described. To date, an effective treatment has not been established for either aceruloplasminemia or symptomatic heterozygous aceruloplasminemia. The present report concerns the beneficial treatment of an 18-year-old girl with extrapyramidal and cerebellar-mediated movement disorder caused by a heterozygous mutation of the ceruloplasmin gene using oral zinc sulphate.

a Department of Psychiatry and Psychotherapy, University of Cologne, Kerpener Strasse 62, 50924 Cologne, Germany

b Department of Neurology, Kliniken der Stadt Köln, Krankenhaus Merheim, Ostmerheimerstrasse 200, 51109 Cologne, Germany

c First Department of Medicine (Neurology), Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu 431-3192, Japan

d Neurological Therapy Centre, Heinrich-Heine-University Dusseldorf, Germany

e University Department of Neurology, UMC-Utrecht, Heidelberglaan 100, 3584 CX, The Netherlands

Corresponding Author InformationCorresponding author. Tel.: +49 221 478 4005; fax: +49 221 478 87123.

PII: S0387-7604(07)00005-8

doi:10.1016/j.braindev.2007.01.001


View previous. 12 of 17 View next.